MAPK8 and bone cancer: Intrathecal administration of D1DR agonist SKF 38393 (Figure 6A-D), D2DR agonist Quinpiride (Figure 6E-H), and D1/D2DR heteromer agonist SKF 83959 (Figure 6I-L) (15 minutes before l-CDL on the 14th day after TCI) reversed l-CDL (15 μg/20 μL, i.t.)induced inhibition of upregulated p-CaMKII, p-ERK, p-JNK, and p-p38 in TCI-induced bone cancer pain.